Format

Send to

Choose Destination
Nat Rev Neurol. 2014 Nov;10(11):643-60. doi: 10.1038/nrneurol.2014.187. Epub 2014 Oct 14.

Maternal immune activation and abnormal brain development across CNS disorders.

Author information

1
Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.
2
Brain Ischemia &Regeneration Group, Department of Biomedicine, University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland.
3
Department of Internal Medicine, Emergency Unit, University Hospital, Petersgraben 2, 4031 Basel, Switzerland.
4
The Nisonger Centre, Ohio State University, 1581 Dodd Drive, Columbus, OH 43210, USA.
5
Pegasus Research, Burggartenstrasse 32, 4103 Bottmingen, Switzerland.

Abstract

Epidemiological studies have shown a clear association between maternal infection and schizophrenia or autism in the progeny. Animal models have revealed maternal immune activation (mIA) to be a profound risk factor for neurochemical and behavioural abnormalities in the offspring. Microglial priming has been proposed as a major consequence of mIA, and represents a critical link in a causal chain that leads to the wide spectrum of neuronal dysfunctions and behavioural phenotypes observed in the juvenile, adult or aged offspring. Such diversity of phenotypic outcomes in the mIA model are mirrored by recent clinical evidence suggesting that infectious exposure during pregnancy is also associated with epilepsy and, to a lesser extent, cerebral palsy in children. Preclinical research also suggests that mIA might precipitate the development of Alzheimer and Parkinson diseases. Here, we summarize and critically review the emerging evidence that mIA is a shared environmental risk factor across CNS disorders that varies as a function of interactions between genetic and additional environmental factors. We also review ongoing clinical trials targeting immune pathways affected by mIA that may play a part in disease manifestation. In addition, future directions and outstanding questions are discussed, including potential symptomatic, disease-modifying and preventive treatment strategies.

PMID:
25311587
DOI:
10.1038/nrneurol.2014.187
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center